IgA nephropathy and Henoch-Schönlein purpura nephritis

Current Opinion in Pediatrics

Volumn 20, Issue 2, 2008, Pages 163-170

  Sanders, John T ^a   Wyatt, Robert J ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Galactosylation; Henoch Sch nlein purpura nephritis; IgA nephropathy; IgA1

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BENAZEPRIL; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HEPARIN; IMMUNOGLOBULIN A1; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; OMEGA 3 FATTY ACID; PREDNISONE; WARFARIN;

ANAPHYLACTOID PURPURA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIAGNOSTIC TEST; DISEASE FREE SURVIVAL; DRUG MEGADOSE; GLOMERULOSCLEROSIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; LONG TERM CARE; PRIORITY JOURNAL; PROTEINURIA; PROTEOMICS; REVIEW; TONSILLECTOMY; TREATMENT OUTCOME; URINALYSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CAUSALITY; CHILD; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY FAILURE, CHRONIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PURPURA, SCHOENLEIN-HENOCH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 40549112311     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3282f4308b     Document Type: Review

References (57)

1. Delos Santos NM, Wyatt RJ. Pediatric IgA nephropathies: clinical aspects and therapeutic approaches. Semin Nephrol 2004; 24:269-286.
2. Meadow SR, Scott DG. Berger disease: Henoch-Schonlein syndrome without the rash. J Pediatr 1985; 106:27-32.
3. Waldo FB. Is Henoch-Schonlein purpura the systemic form of IgA nephropathy? Am J Kidney Dis 1988; 12:373-377.
4. Allen AC, Harper SJ, Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 1995; 100:470-474.
5. Hiki Y, Horii A, Iwase H, et al. O-linked oligosaccharide on IgA1 hinge region in IgA nephropathy. Fundamental study for precise structure and possible role. Contrib Nephrol 1995; 111:73-84.
6. Mestecky J, Tomana M, Crowley-Nowick PA, et al. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol 1993; 104:172-182.
7. Allen AC, Willis FR, Beattie TJ, et al. Abnormal IgA glycosylation in Henoch-Schonlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transplant 1998; 13:930-934.
8. Amore A, Cirina P, Conti G, et al. Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells. J Am Soc Nephrol 2001; 12:1862-1871.
9. Moldoveanu Z, Wyatt RJ, Lee JY, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 2007; 71:1148-1154. The measurement of Gal-d IgA1 could soon become an important, noninvasive diagnostic test for IgAN.
10. Novak J, Tomana M, Matousovic K, et al. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 2005; 67:504-513.
11. Tomana M, Matousovic K, Julian BA, et al. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 1997; 52:509-516.
12. Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999; 104:73-81.
13. Mattu TS, Pleass RJ, Willis AC, et al. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fc alpha receptor interactions. J Biol Chem 1998; 273:2260-2272.
14. Renfrow MB, Cooper HJ, Tomana M, et al. Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation fourier transform-ion cyclotron resonance mass spectrometry. J Biol Chem 2005; 280:19136-19145.
15. Renfrow MB, Mackay CL, Chalmers MJ, et al. Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: implications for IgA nephropathy. Anal Bioanal Chem 2007; 389:1397-1407.
16. Suzuki H, Moldoveanu Z, Hall S, et al. IgA nephropathy: characterization of IgG antibodies specific for galactose-deficient IgA1. Contrib Nephrol 2007; 157:129-133.
17. Ariceta G, Gallego N, Lopez-Fernandez Y, et al. Long-term prognosis of childhood IgA nephropathy in adult life [in Spanish]. Med Clin (Barc) 2001; 116:361-364.
18. Kusumoto Y, Takebayashi S, Taguchi T, et al. Long-term prognosis and prognostic indices of IgA nephropathy in juvenile and in adult Japanese. Clin Nephrol 1987; 28:118-124.
19. Nozawa R, Suzuki J, Takahashi A, et al. Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation. Clin Nephrol 2005; 64:171-179.
20. Ronkainen J, Ala-Houhala M, Autio-Harmainen H, et al. Long-term outcome 19 years after childhood IgA nephritis: a retrospective cohort study. Pediatr Nephrol 2006; 21:1266-1273.
21. Wyatt RJ, Kritchevsky SB, Woodford SY, et al. IgA nephropathy: long-term prognosis for pediatric patients. J Pediatr 1995; 127:913-919.
22. Yoshikawa N, Ito H. Nakamura H: IgA nephropathy in children from Japan. Clinical and pathological features. Child Nephrol Urol 1988; 9:191-199.
23. Hastings MC, Delos Santos NM, Wyatt RJ. Renal survival in pediatric patients with IgA nephropathy. Pediatr Nephrol 2007; 22:317-318.
24. Coppo R, Andrulli S, Amore A, et al. Predictors of outcome in Henoch-Schönlein nephritis in children and adults. Am J Kidney Dis 2006; 47:993-1003. This study showed that persistence of significant proteinuria is a poor prognostic marker for HSPN. This implies that treatment strategies should be targeted at reduction of proteinuria.
25. Scharer K, Krmar R, Querfeld U, et al. Clinical outcome of Schonlein-Henoch purpura nephritis in children. Pediatr Nephrol 1999; 13:816-823.
26. Butani L, Morgenstern BZ. Long-term outcome in children after Henoch-Schonlein purpura nephritis. Clin Pediatr (Phila) 2007; 46:505-511.
27. Chang WL, Yang YH, Wang LC, et al. Renal manifestations in Henoch-Schonlein purpura: a 10-year clinical study. Pediatr Nephrol 2005; 20:1269-1272.
28. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med 1993; 118:201-210.
29. Hogg RJ, Silva FG, Wyatt RJ, et al. Prognostic indicators in children with IgA nephropathy-report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 1994; 8:15-20.
30. Yoshikawa N, Ito H, Nakamura H. Prognostic indicators in childhood IgA nephropathy. Nephron 1992; 60:60-67.
31. Lau KK, Gaber LW, Delos Santos NM, et al. Pediatric IgA nephropathy: clinical features at presentation and outcome for African-Americans and Caucasians. Clin Nephrol 2004; 62:167-172.
32. Lemley KV, Lafayette RA, SafaiM, et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61:1475-1485.
33. Hara M, Yanagihara T, Kihara I. Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schonlein-Henoch purpura nephritis. Clin J Am Soc Nephrol 2007; 2:231-238. Urinary podocyte excretion is another marker for disease severity in pediatric IgAN and HSPN.
34. Ichikawa I, Ma J, Motojima M, et al. Podocyte damage damages podocytes: autonomous vicious cycle that drives local spread of glomerular sclerosis. Curr Opin Nephrol Hypertens 2005; 14:205-210.
35. Mir S, Yavascan O, Mutlubas F, et al. Clinical outcome in children with Henoch-Schonlein nephritis. Pediatr Nephrol 2007; 22:64-70.
36. Halling SF, Soderberg MP, Berg UB. Henoch Schonlein nephritis: clinical findings related to renal function and morphology. Pediatr Nephrol 2005; 20:46-51.
37. Wyatt RJ. The complement system in IgA nephropathy and Henoch-Schonlein purpura: functional and genetic aspects. Contrib Nephrol 1993; 104:82-91.
38. Brenchley PE, Coupes B, Short CD, et al. Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy. Kidney Int 1992; 41:933-937.
39. Wyatt RJ, Kanayama Y, Julian BA, et al. Complement activation in IgA nephropathy. Kidney Int 1987; 31:1019-1023.
40. Zwirner J, Burg M, Schulze M, et al. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int 1997; 51:1257-1264.
41. Lu JH, Thiel S, Wiedemann H, et al. Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the proenzyme C1r2C1s2 complex, of the classical pathway of complement, without involvement of C1q. J Immunol 1990; 144:2287-2294.
42. Thiel S, Vorup-Jensen T, Stover CM, et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997; 386:506-510.
43. Hisano S, Matsushita M, Fujita T, et al. Activation of the lectin complement pathway in Henoch-Schonlein purpura nephritis. Am J Kidney Dis 2005; 45:295-302.
44. Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006; 17:1724-1734. This study provided further evidence that complement activation via the lectin pathway is associated with severity of IgAN in adults.
45. Haubitz M, Wittke S, Weissinger EM, et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 2005; 67:2313-2320.
46. Julian BA, Witke S, Novak J, et al. Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis (in press).
47. Park MR, Wang EH, Jin DC, et al. Establishment of a 2-D human urinary proteomic map in IgA nephropathy. Proteomics 2006; 6:1066-1076.
48. Tomino Y. Can urine polypeptide profiles be used to diagnose IgA nephropathy? Nat Clin Pract Nephrol 2005; 1:72-73.
49. Lau KK, Wyatt RJ, Moldoveanu Z, et al. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schonlein purpura. Pediatr Nephrol 2007; 22:2067-2072.
50. Julian BA, Wittke S, Haubitz M, et al. Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases. World J Urol 2007; 25:467-476.
51. Wyatt RJ, Hogg RJ. Evidence-based assessment of treatment options for children with IgA nephropathies. Pediatr Nephrol 2001; 16:156-167.
52. Yoshikawa N, Ito H, Sakai T, et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 1999; 10:101-109.
53. Yoshikawa N, Honda M, Iijima K, et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 2006; 1:511-517.
54. Chan JC, Mahan JD, Trachtman H, et al. Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study. Pediatr Nephrol 2003; 18:1015-1019.
55. Hogg RJ, Lee J, Nardelli N, et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006; 1:467-474.
56. Kawasaki Y, Takano K, Suyama K, et al. Efficacy of tonsillectomy pulse therapy versus multiple-drug therapy for IgA nephropathy. Pediatr Nephrol 2006; 21:1701-1706.
57. Coppo R, Peruzzi L, Amore A, et al. IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18:1880-1888.